Huberman LabPeptides: The Science, Uses & Safety | Dr. Abud Bakri
CHAPTERS
- 0:00 – 3:37
Celebrity “trinity stack”: GLP-1s + growth-hormone modulators + androgen therapies
The episode opens with a candid description of a popular transformation protocol in high-performance circles: combining a GLP-1 agonist, growth hormone (or secretagogues), and testosterone/androgen modulation. Bakri and Huberman frame this as effective for rapid body recomposition, but emphasize that long-term safety is uncertain.
- •“Trinity stack” components: GLP-1 drugs, GH or GH secretagogues, and TRT/androgen modulation
- •Observed outcomes: rapid fat loss and muscle gain in short time windows
- •Cost/access shapes which compounds people use (GH vs secretagogues)
- •Open question: whether these dramatic changes are healthy long-term
- 3:37 – 6:37
What peptides are: a “language” of the body and the key receptor vs. non-receptor distinction
Huberman and Bakri define peptides broadly as biological signaling molecules, then introduce an important organizing framework: peptides with known receptors (clear targets, predictable effects) versus peptides without identified receptors (harder to model, often driven by animal/anecdotal data). This sets up why GLP-1s feel “cleaner” mechanistically than compounds like BPC-157 or TB-4.
- •Peptides as part of cell-to-cell communication alongside steroid hormones
- •Two buckets: known-receptor peptides (e.g., GLP-1 agonists) vs. no-known-receptor peptides (e.g., BPC-157, TB-4)
- •Why receptor knowledge matters for clinical predictability and safety inference
- •Possible non-receptor mechanisms: protein modulation, epigenetic/DNA-groove binding (notably “Russian peptides”)
- 6:37 – 11:19
BPC-157 origin story: gut-derived ‘body protection’ idea from Pavlov to Croatian discovery
Bakri explains how BPC-157 emerged from a lineage of thinking about cytoprotective factors in gastric juices—starting with Pavlov’s work and later stress biology observations. A Croatian group in the early 1990s isolated a large gastric protein (BPC) and identified the 15–amino acid fragment BPC-157 as the bioactive piece driving many reported effects.
- •Historical backdrop: Pavlov’s gastric juice research and early therapeutic use concepts
- •Hans Selye stress adaptation findings: stress damages gastric lining and shrinks thymus
- •Croatian group (1991) identifies large BPC protein; BPC-157 is a 15-AA fragment
- •Clarification: humans make the larger BPC protein; BPC-157 is not clearly endogenous as-is
- •Broader theme: organs may contain ‘signature peptides’ with organ-relevant effects
- 11:19 – 19:28
BPC-157 animal data: tissue repair, angiogenesis signals, and surprising neurologic effects
They review striking animal studies where BPC-157 appears to speed healing across multiple tissues (tendons, burns, ulcers) and affects vascular signaling pathways like VEGF. The discussion expands to unusual neurological and behavioral findings in animal models (alcohol intoxication/withdrawal paradigms) and human anecdotes suggesting gut–brain axis involvement.
- •Injury models: tendon/ligament cuts, ACL injury, burn wounds; faster healing with BPC-157
- •Anti-stress framing: prevents stress-related gastric ulceration in severe injury settings
- •Mechanistic hypotheses: VEGF/angiogenesis, nitric oxide modulation, immune/healing cell recruitment
- •Tendon model finding: increased growth hormone receptor expression locally
- •Neurologic/behavioral findings: altered intoxication/withdrawal behaviors in animals
- •Human anecdotes: possible blunting of stimulants (e.g., Adderall), reports of anhedonia—suggesting ‘homeostatic’ effects
- 19:28 – 25:16
BPC-157 safety evidence gaps: LD50, limited human trials, and systemic vs local exposure questions
Huberman presses for documented adverse events and what formal toxicology exists. Bakri notes the absence of a known LD50, extremely high-dose animal exposures with few reported harms, and only small early human trials (rectal/enema forms) with limited accessible data—highlighting how little is truly known about human pharmacokinetics and systemic distribution.
- •No established LD50 for BPC-157; complicates regulatory confidence
- •Animal studies: very high-dose injections reported without clear adverse effects
- •Human evidence: small phase 1/2 rectal/enema trials in ulcerative colitis; limited public data beyond abstracts
- •Important uncertainty: oral/rectal BPC-157 may not appear in blood—unclear systemic exposure vs local gut action
- •Injectable use is presumed systemic, but distribution and dynamics remain poorly characterized
- •Doping context: newer work can detect fragments for anti-doping purposes
- 25:16 – 29:30
Legality and regulation: compounding categories, PDA relabeling, and state-by-state enforcement
Bakri explains how BPC-157 sits in a shifting U.S. regulatory landscape: FDA compounding categories, temporary moves to “do not compound,” and strategies like relabeling as pentadecapeptide arginate (PDA). They emphasize that even if federal posture softens, state medical boards and telehealth jurisdiction rules can still place clinicians at risk.
- •BPC-157 is not FDA-approved; legality often framed as ‘research use only’
- •FDA compounding categories (1/2/3) and the 2024 move of multiple peptides to Category 2 (do not compound)
- •Relabeling workaround: BPC-157 sold as pentadecapeptide arginate (PDA); same compound with different salt forms
- •Recent shifts: removed from Category 2 but not clearly placed into Category 1 at the time discussed
- •State medical boards vary; telehealth governed by patient location (not clinician location)
- •Enforcement is inconsistent now but expected to tighten/shift over coming years
- 29:30 – 41:31
Compounding pharmacies vs gray market vs black market: where peptides come from and how quality fails
The conversation broadens from BPC-157 to the peptide supply chain and incentives. Bakri claims most active pharmaceutical ingredients (APIs) originate in China, then get packaged through different channels with varying quality control, while Huberman highlights the consumer risk created by inconsistent testing and batch-to-batch variability.
- •Price and access drive sourcing decisions (pharma vs compounding vs gray market)
- •Compounding economics: clinicians may mark up vials via ‘administrative fees’; patients can ask what the clinician pays vs charges
- •Gray market pattern: ‘for research only’ sites, unusual payment methods, shifting account names
- •Black market: direct-from-China or illicit/unknown synthesis (‘bathtub’ labs)
- •Quality risks: wrong compound substitution (example: retatrutide swapped with melanotan)
- •Core problem: batch-to-batch variability and lack of reliable verification for end users
- 41:31 – 54:19
BPC-157 controversies: tumor/angiogenesis concerns, why evidence is thin, and what trials should measure
Huberman raises a primary safety worry: angiogenesis could theoretically support tumor growth if occult cancers exist. Bakri notes limited cancer signals in animal data but acknowledges most work comes from a single research group, increasing uncertainty; they then brainstorm realistic clinical trial endpoints that could validate or falsify common claims.
- •Main theoretical risk: VEGF/angiogenesis could accelerate growth of existing tumors
- •Counterpoint: no strong carcinogenic signal seen in animal studies; BPC is not viewed as mutagenic
- •Major limitation: much of the animal literature originates from one Croatian group; replication is limited
- •Anecdotal signal: worsening of spider angiomas/vascular lesions in some users
- •Trial ideas/endpoints: ulcerative colitis, GERD vs proton-pump inhibitors, addiction/craving outcomes, post-surgical tendon healing timelines
- •Key unknown: appropriate human dosing—common microgram protocols may be too low for detectable effects
- 54:19 – 1:07:25
Anecdotes and ethics: personal injury recoveries, physician malpractice exposure, and ‘Wild West’ medicine risks
Huberman and Bakri share personal experiences of fast recovery from musculoskeletal injuries, while repeatedly flagging the limitations of anecdote. They then pivot to medical ethics and liability: prescribing non–FDA-approved peptides can expose clinicians to board action and malpractice gaps, and adverse events may trigger lawsuits against multiple parties.
- •Personal stories: Bakri’s triceps tear recovery and Huberman’s neck/trap pain improvement (anecdotal)
- •Not everyone reports benefit; some report adverse mood/energy effects or no effect
- •Ethical framing: best-case (missed breakthrough) vs worst-case (harm at scale) outcomes if data remain absent
- •Clinical reality: hospital prescribing of non-approved peptides is highly risky for physicians
- •Liability pathways: patient may sue physician, compounding pharmacy, and any recommender; malpractice coverage often excludes non-approved peptides
- •Need for structured monitoring/registries to convert ‘anecdata’ into usable safety signals
- 1:07:25 – 1:19:58
Pinealon (EDR): a Russian tripeptide bioregulator for cognition and sleep architecture—how it might work
They introduce pinealon—renamed by them as “EDR” (its amino acid sequence)—and discuss why it may influence cognition and REM sleep despite lacking a known receptor. Bakri frames EDR as an epigenetic/DNA-groove modulator that may improve brain metabolism and performance; Huberman shares self-experimentation suggesting timing and dose strongly shape effects on deep sleep vs REM.
- •Discovery context: Soviet-era peptide research targeting stress, performance, and aging
- •Naming clarification: epithalon is pineal-derived; pinealon/EDR is linked to cortex-derived extracts (often confused)
- •Mechanism hypothesis: binds DNA grooves and modulates gene expression (epigenetic bioregulation)
- •Reported outcomes: reduced brain fog, improved performance under fatigue; vivid dreams and REM changes in some users
- •Practical variables: oral vs injectable, dose sensitivity, and timing (morning vs night)
- •Cautions: possible blood sugar lowering via PPAR-related effects; intense dreams/nightmares for some
- 1:19:58 – 1:29:45
Epithalon (AADG) and the pineal gland: melatonin decline, circadian genes, and longevity claims
The discussion shifts to epithalon as a pineal-derived peptide linked to circadian regulation and possible longevity effects in Russian long-term studies. They address the debated issue of pineal calcification versus functional decline, and review claims that epithalon can influence clock gene expression, hormonal rhythms (including morning cortisol), and systemic aging-related outcomes.
- •Pineal aging: melatonin production declines after puberty; calcification is debated but functional decline is well-noted
- •Epithalon’s proposed actions: upregulate clock genes and restore circadian-appropriate hormonal profiles
- •Khavinson’s long-duration nursing-home study claims: periodic peptide courses associated with reduced mortality (cardio/infection/cancer)
- •Huberman’s interest: neurodegeneration/vision models (RP, glaucoma) suggest possible neuroprotective/DNA-repair relevance
- •Speculation: potential interaction with melanopsin/retinal pathways and light sensitivity
- •Big caveat: much evidence base is Russian/Eastern European literature with limited Western replication
- 1:29:45 – 1:50:14
The thymus: immune aging, thymic involution, and thymic peptides (Thymosin Alpha-1, TB-500, thymulin)
Bakri offers a detailed primer on thymus biology: how it grows in youth, involutes after puberty, and shapes T-cell training and immune robustness over the lifespan. They discuss evidence that thymus removal can worsen outcomes, explore thymic regeneration strategies (e.g., growth hormone cocktails), and differentiate thymic peptides by function and evidence quality.
- •Thymus function: trains naïve T cells to avoid autoimmunity while targeting pathogens/cancers
- •Thymic involution: accelerates after puberty; influenced by sex steroids and corticosteroids; varies by individual
- •Clinical signal: thymus removal during surgeries correlates with increased mortality/autoimmune/cancer risks in some data
- •TRIM trial concept: GH + metformin + DHEA reported to increase thymic size and improve immune markers
- •Thymosin Alpha-1: immune-supportive peptide; approved/used in some contexts internationally; debated effectiveness in sepsis/infection outcomes
- •TB-500/TB-4: linked to actin cytoskeleton and cell migration; used in equine/athletic doping contexts
- •Thymulin: zinc-dependent thymic peptide; may modulate endocrine responsiveness in animal models; emphasizes zinc status
- 1:50:14 – 2:04:01
GHK-Cu (copper peptide): collagen remodeling, skincare ‘glow’ protocols, and topical vs injectable considerations
They explain why GHK-Cu became the ‘aesthetic peptide’: it’s a collagen-associated tripeptide complexed with copper that declines with age and appears to regulate both collagen synthesis and breakdown. Bakri emphasizes formulation quality for topicals, notes limited robust human evidence for injectables, and highlights emerging interest in wound healing and organ repair (e.g., lung connective tissue).
- •GHK-Cu basics: glycine–histidine–lysine + copper; found in type I collagen; declines with age in serum
- •Primary use case: skin quality/collagen remodeling; common in topical skincare
- •Mechanism framing: supports balanced collagen synthesis + breakdown (remodeling)
- •Quality concerns: real formulations often appear blue; poor products may have copper dissociated or degraded peptide
- •Adjunct concepts: potential synergy with red/near-infrared light; post-UV damage repair claims
- •Expanding research interest: wound repair models and exploratory lung/connective tissue regeneration work
- 2:04:01 – 2:20:15
Growth hormone secretagogues: benefits people seek vs risks (insulin resistance, organ growth, cancer promotion)
They outline the landscape of growth hormone secretagogues (e.g., tesamorelin, ipamorelin, MK-677) and why people use them for body composition, recovery, and “youthful” effects. The chapter emphasizes central tradeoffs: GH/IGF-1 can improve certain tissues and may even support thymus regrowth, but can worsen insulin sensitivity and potentially accelerate growth of existing tumors or organs like the prostate.
- •Secretagogues vs GH: stimulate endogenous GH release; vary in pulsatility and side effects (hunger/ghrelin effects)
- •Somatopause framing: GH/IGF-1 decline in 30s; debate about whether replacement helps or harms aging trajectories
- •Potential benefits: skin, recovery, sleep architecture changes, possible thymic regeneration
- •Key risks: impaired insulin sensitivity/A1C rise, possible organ/prostate growth, theoretical tumor growth promotion (not mutagenic)
- •Different compounds: MK-677 (non-peptide, strong ghrelin/hunger effects) vs tesamorelin-based protocols
- •Emerging ‘trinity stack’ concept: GLP-1s used to offset insulin resistance from GH/androgen stacks
- 2:20:15 – 2:48:22
GLP-1 drugs and retatrutide: metabolic revolution, brain/motivation effects, dosing hazards, and patent strategy
They close by discussing GLP-1 agonists as a system-level shift in medicine—potentially preventing healthcare collapse from obesity/diabetes burden—while acknowledging unanswered questions about long-term neurobehavioral and developmental effects. The segment covers dosing pitfalls (including a severe personal adverse event), fertility changes with weight loss, and how retatrutide’s design and patent/biologic classification may shape compounding access and market dominance.
- •GLP-1 impact: large, consistent weight loss effects compared to older drugs; broad cardiometabolic implications
- •Open concerns: ‘motivation/drive’ blunting, social downstream effects of reduced eating/drinking, unknown long-term neuroplasticity effects—especially in youth
- •Clinical approach: lowest effective dose + lifestyle support; risks increase with aggressive dosing and poor nutrition/electrolytes
- •Bakri anecdote: high-dose semaglutide without titration caused severe vomiting—underscores titration importance
- •Fertility: ‘Ozempic babies’ phenomenon—fertility may improve with weight loss and leptin normalization
- •Retatrutide business dynamics: peptide length/biologic classification may extend patents and restrict compounding; compounding vs pharma pricing and access tensions
